Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045488 | 0.92 | OPRM1 (0.42) | CYP2D6ALDH1A1OPRM1MAPK1CYP3A4 | |
| SCHEMBL6045421 | 0.90 | CYP2D6 (0.44) | CYP2D6CHRM2CHRM3ALDH1A1ACHE | |
| Oxalic Acid SCHEMBL6045747 | 0.90 | OPRM1 (0.41) | CYP2D6ALDH1A1OPRM1MAPK1CYP3A4 | |
| Oxalic Acid SCHEMBL6045529 | 0.88 | CYP2D6 (0.42) | CYP2D6CHRM2CHRM3ALDH1A1ACHE | |
| Fumaric Acid SCHEMBL6045570 | 0.86 | SIGMAR1 (0.41) | CYP2D6CHRM2CHRM3ALDH1A1ACHE | |
| Fumaric Acid SCHEMBL6045576 | 0.86 | SIGMAR1 (0.41) | CYP2D6CHRM2CHRM3ALDH1A1ACHE | |
| SCHEMBL6045562 | 0.85 | CHRM2 (0.43) | CYP2D6CHRM2CHRM3ALDH1A1ACHE | |
| SCHEMBL6045636 | 0.85 | DRD4 (0.44) | CYP2D6CHRM2CHRM3ALDH1A1MEN1 | |
| SCHEMBL6045538 | 0.85 | CYP3A4 (0.42) | CYP2D6ALDH1A1ACHEMEN1KMT2A | |
| SCHEMBL6045524 | 0.84 | CHRM2 (0.44) | CYP2D6CHRM2CHRM3ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | claimed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | claimed |
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | CYP2D6 4634/4885CHRM2 630/4885CHRM3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.